Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Trial eligibility depends on the protocol, location, medical history, and investigator review
The top dose produced 20.9% average weight loss over 72 weeks and 20.2% in a direct comparison with semaglutides 13.7%. Its second receptor, GIP, separates tirzepatide from approved single-receptor GLP-1 drugs and helps explain the larger population-level weight loss. That 20.9% came from participants averaging about 105 kg at a BMI of 38, most of whom were sedentary
HbA1c (Hemoglobin A1c) Measures long-term blood sugar control
It produces a pulse of growth hormone and has a relatively short half-life
US$ 27.18
US$ 20.37
US$ 29.19
US$ 21.63
